Korro Bio, Inc. (KRRO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Korro Bio reported revenue of $6.4M, up 181.5% from $2.3M the year before. Net income was -$117.3M (a -1834.5% net margin), or -$12.48 per diluted share. Operating margin was -1906.4%. Operating activities generated -$78.6M of cash, leaving -$79.1M of free cash flow. At fiscal year end, Korro Bio held $113.5M in total assets against $62.1M in total liabilities, including $21.8M of cash and equivalents.
Open the full interactive Korro Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Korro Bio Key Stats
| Share Price | $8.81 |
|---|---|
| Market Cap | $155.2M |
| Revenue YoY Growth | +181.5% |
| 52-Week Range | $5.28 – $51.36 |
| Shares Outstanding | 17.6 million (basic, 2026 Q2) |
Korro Bio Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $37.0M | $14.1M | $0 | $0 | $2.3M | $6.4M |
| Operating Income | -$27.6M | -$84.0M | -$83.0M | -$84.5M | -$91.9M | -$121.9M |
| Pre-Tax Income | -$26.5M | -$84.7M | -$81.6M | -$81.1M | -$83.4M | -$116.6M |
| Income Tax | $35,000 | $15,000 | -$2,000 | $27,000 | $141,000 | $637,000 |
| Net Income | -$26.5M | -$84.7M | -$81.6M | -$81.2M | -$83.6M | -$117.3M |
| Diluted EPS | -$41.00 | -$123.50 | — | -$53.08 | -$9.37 | -$12.48 |
Korro Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.1M | $1.3M | $0 | $0 |
| Net Income | -$18.1M | -$50.0M | -$19.6M | -$18.9M |
| Diluted EPS | -$1.92 | -$5.33 | -$1.69 | -$1.07 |
Korro Bio Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $220.3M | $79.6M | $52.0M | $166.2M | $55.6M | $21.8M |
| Current Assets | $225.1M | $134.7M | $87.5M | $172.7M | $131.5M | $82.4M |
| Total Assets | $264.7M | $185.4M | $121.2M | $221.7M | $226.2M | $113.5M |
| Current Liabilities | $26.6M | $11.4M | $21.0M | $19.5M | $15.0M | $11.9M |
| Total Long-Term Debt | $15.0M | $15.0M | $14.2M | — | — | — |
| Total Liabilities | $72.2M | $54.5M | $52.0M | $51.8M | $65.8M | $62.1M |
| Shareholders' Equity | $192.5M | $130.8M | $69.2M | $169.9M | $160.4M | $51.4M |
Korro Bio Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$45.2M | -$76.1M | -$58.2M | -$67.3M | -$60.1M | -$78.6M |
| Cash From Investing | $10.4M | -$66.1M | $31.1M | $11.2M | -$123.3M | $44.0M |
| Cash From Financing | $56.7M | $1.4M | -$577,000 | $187.8M | $69.4M | $685,000 |
| Free Cash Flow | -$51.9M | -$79.0M | -$58.2M | -$75.1M | -$78.0M | -$79.1M |
Figures from Korro Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Korro Bio financials page for every line item.
Korro Bio Company Profile
| Ticker | KRRO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001703647 |
Frequently Asked Questions
What was Korro Bio's revenue in fiscal 2025?
Korro Bio (KRRO) reported revenue of $6.4M for fiscal 2025.
What is Korro Bio's annual revenue history?
Korro Bio's annual revenue by fiscal year: 2020: $37.0M; 2021: $14.1M; 2022: $0; 2023: $0; 2024: $2.3M; 2025: $6.4M.
What was Korro Bio's net income in fiscal 2025?
Korro Bio reported net income of -$117.3M for fiscal 2025.
What was Korro Bio's earnings per share (EPS) in fiscal 2025?
Korro Bio's diluted EPS was -$12.48 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Korro Bio generate in fiscal 2025?
Korro Bio generated -$79.1M of free cash flow in fiscal 2025.
What was Korro Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Korro Bio reported revenue of $0.
How many shares of Korro Bio are outstanding?
Korro Bio reported a weighted average of 17.6 million basic shares outstanding in 2026 Q2.
What is Korro Bio's market cap?
Based on its latest closing price, Korro Bio (KRRO) has a market capitalization of about $155.2M.
When does Korro Bio's fiscal year end?
Korro Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Korro Bio headquartered?
Korro Bio lists its business address in Cambridge, Massachusetts in its SEC filings.